Rapport Therapeutics Establishes $110 Million At-The-Market Offering

Rapport Therapeutics, Inc. ( (RAPP) ) just unveiled an update.

On January 7, 2026, Rapport Therapeutics, Inc. filed a prospectus supplement to its effective shelf registration statement to register the offer and sale, from time to time, of up to $110 million of its common stock through Leerink Partners LLC and Cantor Fitzgerald & Co. as sales agents under an existing sales agreement dated July 1, 2025. As of the filing date, the company had not yet sold any shares under this arrangement, indicating the filing primarily positions Rapport to tap the capital markets flexibly in the future to support its funding needs without immediately altering its share base.

The most recent analyst rating on (RAPP) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Rapport Therapeutics, Inc. stock, see the RAPP Stock Forecast page.

Spark’s Take on RAPP Stock

According to Spark, TipRanks’ AI Analyst, RAPP is a Neutral.

The score is primarily held back by weak financial performance typical of a pre-revenue biotech (widening losses and increasing cash burn). Strength comes from a strong, low-debt balance sheet and a notable positive corporate catalyst (FDA clearance to move the lead program into Phase 3 with a stated multi-year cash runway). Technicals are neutral-to-weak near term and valuation metrics provide limited support due to negative earnings.

To see Spark’s full report on RAPP stock, click here.

More about Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing therapeutics, with its shares of common stock listed and accessible to public equity investors as it seeks to finance its operations and growth through capital market transactions.

Average Trading Volume: 395,466

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.31B

For an in-depth examination of RAPP stock, go to TipRanks’ Overview page.